Imigran Radis (Sumatriptan)

Sumatriptan is a triptan class medication used to treat migraine by targeting cranial blood vessels and trigeminal nerve pathways.

• Migraine with aura: rapid relief of headache and associated symptoms during an acute attack.
• Migraine without aura: reduction of pain intensity and associated nausea when taken early in the episode.
• Acute migraine attacks: termination of headache phase and improvement of functional ability.

• Sumatriptan acts as an agonist at serotonin 5‑HT1B and 5‑HT1D receptors located on intracranial blood vessels and trigeminal nerve terminals. Activation of these receptors produces cranial vasoconstriction and inhibits the release of pro‑inflammatory neuropeptides, thereby interrupting the pain signaling cascade responsible for migraine attacks.

Sumatriptan may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Chest discomfort: mild pressure or tightness in the chest.
• Tingling or numbness: sensation in fingers or face.
• Flushing: warm feeling and reddening of the skin.
• Dizziness: light‑headed feeling.

Serious or Rare Side Effects

• Serotonin syndrome: potentially life‑threatening condition with agitation, hyperthermia, and muscle rigidity.
• Cardiac ischemia: chest pain or myocardial infarction in susceptible patients.
• Severe allergic reaction: rash, swelling, or difficulty breathing.

When prescribing Sumatriptan, clinicians should consider several precautionary measures to ensure safe use.

• Cardiovascular assessment: evaluate history of coronary artery disease, angina, or uncontrolled hypertension.
• Concomitant serotonergic drugs: avoid use with MAO inhibitors or SSRIs due to risk of serotonin syndrome.
• Age considerations: use with caution in patients over 65 years, as vascular sensitivity may increase.
• Pregnancy and lactation: safety not established; prescribe only if benefit outweighs potential risk.
• Drug interactions: review all current medications for potential interactions before initiating therapy.
• Store at ambient temperature: keep tablets below 25 °C in the original container, protect from moisture and light.

Sumatriptan can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid)

• MAO inhibitors: concurrent use may precipitate serotonin syndrome.
• Ergot alkaloids: combined vasoconstrictive effect increases risk of coronary spasm.
• Certain antidepressants (SSRIs, SNRIs, TCAs): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (ketoconazole, erythromycin): may increase plasma levels of sumatriptan.
• Antihypertensive agents (beta‑blockers, calcium channel blockers): may enhance vasoconstrictive response.